Tech Company Financing Transactions

Amunix Pharmaceuticals Funding Round

Omega Funds, Casdin Capital and Delian Capital participated in a $73 million Series A venture round for Amunix Pharmaceuticals. The funding round was recorded on 3/5/2020.

Transaction Overview

Announced On
3/5/2020
Transaction Type
Venture Equity
Amount
$73,000,000
Round
Series A
Proceeds Purpose
Amunix plans to utilize the Series A proceeds to advance its lead development candidate, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors into the clinic, to progress earlier discovery stage XPAT programs and to initiate XPAC discovery work.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2 Tower Pl. 1100
San Francisco, CA 94080
USA
Email Address
Overview
At Amunix, we are focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. We are leveraging our proprietary T cell engager (XPAT) and cytokine (XPAC) platforms to advance novel prodrugs that overcome the toxicity and immunogenicity challenges common to these therapeutic modalities.
Profile
Amunix Pharmaceuticals LinkedIn Company Profile
Social Media
Amunix Pharmaceuticals Company Twitter Account
Company News
Amunix Pharmaceuticals News
Facebook
Amunix Pharmaceuticals on Facebook
YouTube
Amunix Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Angie You
  Angie You LinkedIn Profile  Angie You Twitter Account  Angie You News  Angie You on Facebook
Chief Financial Officer
Zeeshan Merchant
  Zeeshan Merchant LinkedIn Profile  Zeeshan Merchant Twitter Account  Zeeshan Merchant News  Zeeshan Merchant on Facebook
Chief Medical Officer
Mika Derynck
  Mika Derynck LinkedIn Profile  Mika Derynck Twitter Account  Mika Derynck News  Mika Derynck on Facebook
Chief Operating Officer
Maninder Hora
  Maninder Hora LinkedIn Profile  Maninder Hora Twitter Account  Maninder Hora News  Maninder Hora on Facebook
Chief Scientific Officer
Bryan Irving
  Bryan Irving LinkedIn Profile  Bryan Irving Twitter Account  Bryan Irving News  Bryan Irving on Facebook
Chief Technical Officer
Volker Schellenberger
  Volker Schellenberger LinkedIn Profile  Volker Schellenberger Twitter Account  Volker Schellenberger News  Volker Schellenberger on Facebook
Vice President
Robert Jones
  Robert Jones LinkedIn Profile  Robert Jones Twitter Account  Robert Jones News  Robert Jones on Facebook
Vice President
Nabeela Rasheed
  Nabeela Rasheed LinkedIn Profile  Nabeela Rasheed Twitter Account  Nabeela Rasheed News  Nabeela Rasheed on Facebook
Vice President
Geetha Shankar
  Geetha Shankar LinkedIn Profile  Geetha Shankar Twitter Account  Geetha Shankar News  Geetha Shankar on Facebook
Vice President
Gary Taniguchi
  Gary Taniguchi LinkedIn Profile  Gary Taniguchi Twitter Account  Gary Taniguchi News  Gary Taniguchi on Facebook
VP - Bus. Development
Darcy Mootz
  Darcy Mootz LinkedIn Profile  Darcy Mootz Twitter Account  Darcy Mootz News  Darcy Mootz on Facebook
VP - Operations
Ursula McCurry
  Ursula McCurry LinkedIn Profile  Ursula McCurry Twitter Account  Ursula McCurry News  Ursula McCurry on Facebook
VP - Regulatory Affairs
Anne Keane
  Anne Keane LinkedIn Profile  Anne Keane Twitter Account  Anne Keane News  Anne Keane on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/5/2020: OutMatch venture capital transaction
Next: 3/5/2020: BoxLock venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on tech company VC transactions. All VC database entries reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary